NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Insulin Resistance in Severely Obese Patients
- Conditions
- ObesityInsulin ResistanceDiabetes
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2010-03-18
- Target Recruit Count
- 48
- Registration Number
- NCT00275223
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT00275002
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
- Conditions
- Nodal Marginal Zone B-cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaStage III Adult Immunoblastic Large Cell LymphomaStage III Grade 2 Follicular LymphomaAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Recurrent Adult Acute Myeloid LeukemiaRecurrent Adult Burkitt Lymphoma
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT00275080
- Locations
- 🇨🇦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada
🇨🇦Chedoke-McMaster Hospitals, Hamilton, Ontario, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
- Conditions
- Stage II Ovarian Epithelial CancerFallopian Tube CancerPrimary Peritoneal Serous AdenocarcinomaRecurrent Ovarian Epithelial CancerStage I Ovarian Epithelial Cancer
- Interventions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2015-11-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT00275028
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2012-10-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 104
- Registration Number
- NCT00273910
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
ZD6474 to Treat Advanced Brain Cancer in Patients
- Conditions
- Recurrent High-Grade GliomasProgressive Low-Grade GliomasMalignant Gliomas
- First Posted Date
- 2006-01-05
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 83
- Registration Number
- NCT00272350
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Does Metabolic Syndrome Exist in Anorexia Nervosa?
- Conditions
- Anorexia NervosaMetabolic Syndrome
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2012-12-18
- Target Recruit Count
- 50
- Registration Number
- NCT00271921
- Locations
- 🇺🇸
St. Luke's Roosevelt Hosptial Center, New York, New York, United States
🇺🇸New York State Psychiatric Institute/Columbia University, New York, New York, United States
Frequent Hemodialysis Network: Nocturnal Trial
- Conditions
- End Stage Renal DiseaseHemodialysis
- Interventions
- Behavioral: Nocturnal home hemodialysis
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2010-03-03
- Target Recruit Count
- 150
- Registration Number
- NCT00271999
- Locations
- 🇺🇸
Wake Forest University - Core center plus other centers in U.S. and Canada, Winston-Salem, North Carolina, United States
Bevacizumab for Recurrent Malignant Glioma
- Conditions
- Recurrent High-Grade GliomasMalignant Gliomas
- Interventions
- First Posted Date
- 2006-01-02
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 88
- Registration Number
- NCT00271609
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
- Conditions
- Adult Giant Cell GlioblastomaAdult GliosarcomaRecurrent Adult Brain NeoplasmAdult Anaplastic AstrocytomaAdult Mixed GliomaAdult Anaplastic OligodendrogliomaAdult Glioblastoma
- Interventions
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 83
- Registration Number
- NCT00268385
- Locations
- 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States